Guest guest Posted July 6, 2009 Report Share Posted July 6, 2009 Ann Rheum Dis. Published Online First: 5 July 2009. doi:10.1136/ard.2008.106617 BMJ Publishing Group Ltd & European League Against Rheumatism. -------------------------------------------------------------------------------- Extended Report Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy (the CAMERA study) S M M Verstappen 1, M F Bakker 1, A H M Heurkens 2, M J van der Veen 3, A A Kruize 1, M A W Geurts 4, J W J Bijlsma 1 and J W G s 1* 1 University Medical Center Utrecht, Utrecht, Netherlands 2 Meander Medical Center, Amersfoort, Netherlands 3 St Jansdal Hospital, Harderwijk, Netherlands 4 St Antonius Hospital, Nieuwegein, Netherlands Abstract Objective: To evaluate toxicity profiles in patients with rheumatoid arthritis (RA) treated either according to an intensive or a conventional treatment strategy approach with methotrexate (MTX) and to study factors associated with MTX related toxicity. Methods: Data were used from the CAMERA study in which clinical efficacy of an intensive treatment strategy with MTX was more beneficial compared to a conventional treatment strategy approach. In the present study, data on adverse events were compared between the two treatment groups. Logistic regression analyses were used to identify possible associations between factors assessed at baseline and withdrawal due to MTX related adverse events or liver toxicity at follow-up. Results: Although significantly more patients in the intensive treatment group experienced MTX related adverse events compared to the conventional treatment group, all recorded adverse events were relatively mild. A higher Body Mass Index (BMI) was significantly associated with withdrawal due to MTX related adverse events in the multiple regression analyses. There was a trend towards an association between diminished creatinine clearance and MTX withdrawal. For liver toxicity, increased serum liver enzymes at baseline were associated with liver toxicity during follow-up. Conclusion: Although the occurrence of adverse events in the intensive treatment group was higher than in the conventional treatment group, the previously observed clinical efficacy of an intensive treatment strategy seems to outweigh the observed toxicity profiles. When starting MTX, attention should be given to patients with a high BMI and those with increased levels of liver enzymes and decreased renal function. http://ard.bmj.com/cgi/content/abstract/ard.2008.106617v1?papetoc Not an MD Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.